Bexagliflozin Patent Expiration

Bexagliflozin is Used for improving glycemic control in adults with type 2 diabetes. It was first introduced by Theracosbio Llc in its drug Brenzavvy on Jan 20, 2023.


Bexagliflozin Patents

Given below is the list of patents protecting Bexagliflozin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Brenzavvy US8987323 Crystalline form of benzylbenzene SGLT2 inhibitor May 14, 2032 Theracosbio
Brenzavvy US10533032 Crystalline form of benzylbenzene SGLT2 inhibitor Jul 03, 2031 Theracosbio
Brenzavvy US10981942 Crystalline form of benzylbenzene SGLT2 inhibitor Jun 13, 2031 Theracosbio
Brenzavvy US7838499 Benzylbenzene derivatives and methods of use Jan 30, 2029 Theracosbio
Brenzavvy US8106021 Benzylbenzene derivatives and methods of use Aug 22, 2028 Theracosbio
Brenzavvy US8802637 Benzylbenzene derivatives and methods of use Aug 22, 2028 Theracosbio



Bexagliflozin's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List